We are pleased to announce the addition of the new selective PPARδ agonist, seladelpar (Livdelzi®, Lyvdelzi®) to the hepatology drug interaction checker. Seladelpa is indicated for primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid, in adults who are non-responsive to ursodeoxycholic acid alone, or who cannot tolerate ursodeoxycholic acid.
All our Interaction Summary Tables have been updated to include seladelpar, and a downloadable update is available for our mobile apps.
Find the PK Factsheet for seladelpar here.
